Series on Cancer Therapy

Check out our Series of Review articles on emerging concepts in cancer therapy, novel therapeutic approaches and the challenges in translating preclinical work to the clinic. 


  • Nature Cancer pictorial

    View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.


    • CAR T cell therapies have made great strides in the clinic; however, multiple hurdles limit the efficacy of this approach for solid tumors. A new study has developed an optimized, dual-targeting CAR T cell that overcomes several of these challenges by enhancing T cell persistence and reducing therapy escape due to antigen loss.

      • Tiffany R. King-Peoples
      • Avery D. Posey Jr.
      News & Views
    • Pseudouridine is the most abundant RNA modification, but its biological role remains poorly understood. A study now finds dysregulated pseudouridine synthase PUS7 in glioblastoma and demonstrates that pharmacological inhibition of PUS7 leads to reduced tumorigenesis, which underpins the therapeutic potential of targeting epitranscriptomic regulators in cancer.

      • Virginia Morón-Calvente
      • Sandra Blanco
      News & Views
    • Combining radiation and immune checkpoint blockade is a promising treatment strategy, yet the mechanisms and optimal dosing strategies are not well known. A new study finds that a specific radiation dose can activate secretory club cells to promote the anti-tumor effects of radiotherapy combined with immunotherapy in NSCLC.

      • Ralph R. Weichselbaum
      • Sean P. Pitroda
      News & Views
    • Ding and colleagues discuss the era of pan-cancer analysis, covering the fundamental insights gained, unique opportunities and challenges, and the future of such approaches in the basic and clinical space.

      • Feng Chen
      • Michael C. Wendl
      • Li Ding
      Review Article
    • Drug resistance may pre-exist or arise during therapy, but how precisely cancer treatment itself influences these processes is a major gap in the understanding of therapy resistance in cancer. A study of acute lymphocytic leukemia now provides direct evidence of thiopurine-induced mutations in the gene encoding the tumor suppressor p53 that result in multi-drug-resistant relapse.

      • Nikki A. Evensen
      • William L. Carroll
      News & Views
  • What happens to a manuscript after submission? How does the editor reach a decision? What is the editor’s role during peer review? We take a look into the editorial process at Nature Cancer.

  • The Biden administration has proposed a new agency to drive innovation in health research, including cancer. The focus on cancer and accelerated development is welcome, but for the time being, whether and how these plans will materialize is less clear.

  • Social media have emerged as a key communication tool for scientists. Here we explore how to reap the benefits and avoid the pitfalls of social networking.

  • The treatment of triple-negative breast cancer remains chemotherapy based and lacks targeted drugs. However, immunotherapy combinations have shown promising activity, targeted chemotherapy options via antibody–drug conjugates are in the clinic, and molecular means of identifying targetable subsets are on the horizon. This Clinical Outlook discusses current and future possibilities for treating triple-negative breast cancer.

    • Lisa A. Carey
    Clinical Outlook
  • Making data available is essential for validating and furthering scientific discoveries. Helping authors navigate whether, how and in what form to share the data is also essential.

Clinical Cancer Genomics

Clinical Cancer Genomics

Advances in sequencing and genomic technologies are rapidly expanding our understanding of cancer and in turn the role of genomics in clinical oncology.